CAR Immune Cell Preparation Technology Service
Service Overview
JWE focuses on antibody therapeutics and cellular immunotherapy development, with team members averaging over 10 years of project experience. Leveraging phage and yeast surface display platforms, JWE provides VHH, scFv, and Fab antibody discovery services, as well as CAR-T/CAR-NK lead antibody sequence design and downstream functional development, establishing a solid foundation for high-quality CAR cell development.
Overview of CAR-T/NK Immunotherapy
CAR-T (Chimeric Antigen Receptor T-Cell Therapy) is a T-cell–based immunotherapy. CAR-NK technology is similar but utilizes NK cells instead of T cells. By introducing VHH or scFv fragments into T/NK cells through genetic engineering, these cells acquire specific tumor-recognition capability and release effector molecules to efficiently eliminate target cells.
Compared with conventional scFv antibodies, camelid-derived VHH nanobodies have a smaller molecular weight (~15 kDa) and excellent structural stability, making them ideal lead candidates for CAR-T development. JWE owns a dedicated alpaca facility, enabling the production of clean-background, well-characterized VHH antibodies.
Lead Antibody Discovery for CAR Cells
- Camelid nanobody (VHH) development
- scFv antibody development and validation
- Rapid screening of high-affinity, high-specificity antibody sequences using proprietary display platforms to support downstream CAR construction
CAR Cell Activity Characterization
- CAR Expression Analysis: Verification of membrane localization and expression of antibody fragments on T/NK cells
- Target Recognition & Specificity Assessment: Antigen-binding specificity, anti-idiotype testing, and antigen-recognition validation using Fab-format antibodies
- Cytokine Release Assays: ELISpot, ICS, and flow cytometry analysis of IL-1, IL-12 family cytokines, and γ-chain co-receptor family factors
- In Vitro Cytotoxicity Assays: Evaluation of CAR-T/NK cytolytic activity and off-target toxicity
- CAR Cell Proliferation Assessment: MTT, MTS, CCK-8, and CFSE flow cytometry to monitor activation and proliferation
- Viability & Biodistribution Analysis: Assessment of long-term viability and distribution under in vitro and simulated physiological conditions
Platform Advantages
- One-stop CAR cell development: from antibody discovery and CAR construction to functional validation
- Established technical route: combining phage and yeast display platforms with extensive experience and high success rates
- Rigorous quality control: standardized facilities, cGMP-compliant documentation, and optional handwritten laboratory notebooks
- Highly customized service: tailored experimental design based on client requirements to meet individualized project needs
